[{"id":"d557545c-a8fc-4f7f-9d63-eb284cbe8b60","acronym":"AMPLIFY-7P","url":"https://clinicaltrials.gov/study/NCT05726864","created_at":"2023-02-14T18:02:24.073Z","updated_at":"2024-07-02T16:35:05.951Z","phase":"Phase 1/2","brief_title":"A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors","source_id_and_acronym":"NCT05726864 - AMPLIFY-7P","lead_sponsor":"Elicio Therapeutics","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12 • KRAS G12S • NRAS G12D • NRAS G12 • NRAS G13 • NRAS G12S • NRAS G12V","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12 • KRAS G12S • NRAS G12D • NRAS G12 • NRAS G13 • NRAS G12S • NRAS G12V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ELI-002 7P"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 04/14/2023","start_date":" 04/14/2023","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-05-03"},{"id":"ccf0a3d0-2d12-4172-9a35-f6327f190184","acronym":"","url":"https://clinicaltrials.gov/study/NCT05254184","created_at":"2022-02-24T14:52:57.088Z","updated_at":"2024-07-02T16:35:22.368Z","phase":"Phase 1","brief_title":"KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC","source_id_and_acronym":"NCT05254184","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12R • KRAS G12A • KRAS G12 • KRAS G13","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12R • KRAS G12A • KRAS G12 • KRAS G13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-01-24"},{"id":"39082f6c-8d92-4c46-9e0c-a8aeaf83e623","acronym":"","url":"https://clinicaltrials.gov/study/NCT05173805","created_at":"2021-12-30T14:55:47.563Z","updated_at":"2024-07-02T16:35:42.768Z","phase":"Phase 1/2","brief_title":"Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation","source_id_and_acronym":"NCT05173805","lead_sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","biomarkers":" PD-L1 • KRAS • MSI • PD-1","pipe":" | ","alterations":" KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12","tags":["PD-L1 • KRAS • MSI • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YL-15293"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 150","initiation":"Initiation: 01/30/2022","start_date":" 01/30/2022","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-07-18"},{"id":"b2c74ab4-c1bb-4e58-a7dd-cb64d3bac04a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05651269","created_at":"2022-12-15T15:58:36.795Z","updated_at":"2024-07-02T16:35:59.048Z","phase":"Phase 2","brief_title":"Milciclib in Combination With Gemcitabine in Advanced NSCLC","source_id_and_acronym":"NCT05651269","lead_sponsor":"Tiziana Life Sciences LTD","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12A • KRAS G12 • KRAS G12S • KRAS G13","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12A • KRAS G12 • KRAS G12S • KRAS G13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • milciclib (TZLS-201)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2022-12-15"}]